CALDERWOOD & HARKNESS LLP Attorneys at Law
599 Lexington Avenue, 36th Floor New York, NY 10022, United States
Telephone: (212) 554-7000 Facsimile: (212) 554-7001 www.calderwoodharkness.com
February 15, 2024
VIA SECURE DOCUMENT PORTAL AND EMAIL
Ms. Fiona Gallagher Chief Financial Officer Solstice Biomedical Devices Ltd. Unit 14, Corrib Technology Park, Headford Road Galway, H91 XR72 Ireland
Re: Information and Document Request — Tax Opinion Engagement (Matter No. 1037-00007) Should-Level Tax Opinion on the Proposed Migration of the intellectual Property Portfolio from Solstice Medical Technologies Inc. to Solstice IP Holdings Designated Activity Company
Dear Ms. Gallagher:
We refer to the engagement letter dated February 9, 2024, between Calderwood & Harkness LLP ("C&H" or the "Firm") and Solstice Biomedical Devices Ltd. ("SBD" or the "Company"), pursuant to which C&H was retained to prepare and deliver a should-level federal income tax opinion in connection with the proposed intercompany transfer of certain intellectual property assets from Solstice Medical Technologies Inc. ("SMT Inc.") to Solstice IP Holdings Designated Activity Company ("SIP Holdings") and the related licensing-back arrangement (collectively, the "Transaction"). As you are aware, the engagement was formally opened on February 12, 2024, following completion of our conflicts clearance on February 11, 2024, which identified no conflicts of interest.
The purpose of this letter is to set forth, in comprehensive detail, the factual materials, documents, data, and information that C&H requires in order to prepare and deliver the should-level tax opinion contemplated by the engagement letter. Our opinion will address, among other things, the US federal income tax consequences of the proposed IP transfer under Sections 367(d), 482, and related provisions of the Internal Revenue Code of 1986, as amended (the "Code"), including the application of the base erosion and anti-abuse tax ("BEAT") under Section 59A and the global intangible low-taxed income ("GILTI") provisions under Section 951A, as well as the availability of treaty benefits under the Convention between the Government of the United States of America and the Government of Ireland for the Avoidance of Double Taxation (the "US-Ireland Income Tax Treaty"). We understand that the target effective date for the IP transfer and the commencement of the license-back arrangement is March 1, 2024. Given this timeline, your prompt attention to this request is essential to our ability to deliver the opinion in advance of, or concurrently with, the closing of the Transaction.
The responsible partner for this engagement is Sylvia Hartwell, and the billing partner is Leonard Cross. Day-to-day communications and questions regarding this information request should be directed to Leila Nazari, lead associate, at (212) 554-7218 or lnazari@calderwoodharkness.com, or to Robert Jansen, working associate, at (212) 554-7345 or rjansen@calderwoodharkness.com. We will coordinate as necessary with SBD's Irish tax advisors at Harrington & Cahill (Niamh O'Sullivan, Tax Partner), the Company's US tax return preparer at Lattimore & Stern CPAs LLP (David Lattimore, CPA), the Company's auditors at Pemberton Hale LLP (Aisling Brennan, Lead Audit Partner), and Irish legal counsel at Dalton Byrne & Partners (Séamus Dalton, Partner). We would ask that you facilitate introductions to the extent we have not already been placed in contact with each of these advisors.
Set forth below is our detailed request, organized by category. Unless otherwise indicated, we request complete and unredacted copies of all responsive documents, together with any schedules, exhibits, appendices, or attachments thereto.
I. ORGANIZATIONAL AND CORPORATE DOCUMENTS
A. Group Structure and Organizational Charts
1. Please provide a current organizational chart of the Solstice Biomedical Devices Ltd. group depicting all direct and indirect subsidiaries, affiliates, and related entities, including, without limitation, the following:
(a) Solstice Biomedical Devices Ltd. (Companies Registration Office ("CRO") No. 587241) — the Irish parent company;
(b) Solstice Medical Technologies Inc. (Delaware Secretary of State File No. 7482916; Employer Identification Number 84-3291507) — the US subsidiary; and
(c) Solstice IP Holdings DAC (CRO No. 714538) — the newly incorporated Irish intellectual property holding entity.
2. The organizational chart should clearly depict all ownership percentages and holding structures, including the interests of the following shareholders of SBD:
(a) Pinnacle Growth Equity Partners Fund III, L.P. — holding a 62.3% equity stake in SBD, together with identification of its general partner, Pinnacle Growth Equity Advisors III LLC (Managing Partner: Jonathan Whitfield);
(b) Morrissey Family Holdings Unlimited Company (CRO No. 492103) — holding an 18.4% equity stake in SBD on behalf of Dr. Cathal Morrissey, Chief Executive Officer;
(c) Fiona Gallagher — holding a 2.1% equity stake in SBD; and
(d) Remaining management and other holders — collectively holding the remaining 17.2% equity stake.
3. In addition, please provide both a pre-transaction organizational chart and a post-transaction organizational chart that clearly illustrate the migration of the intellectual property portfolio from SMT Inc. to SIP Holdings, together with the intercompany loan, equity contribution, license-back arrangement, cost-plus R&D services arrangement, and rest-of-world license agreements that form part of the Transaction.
B. SIP Holdings Incorporation Documents
4. Certificate of incorporation for Solstice IP Holdings DAC, which we understand was incorporated on January 18, 2024, and assigned CRO No. 714538.
5. The constitution (memorandum and articles of association) of SIP Holdings, as adopted at the time of incorporation or as subsequently amended.
6. Details of the share capital of SIP Holdings, including confirmation that the authorized and issued share capital consists of €1,000 in ordinary shares, 100% of which are held by Solstice Biomedical Devices Ltd.
7. Board resolutions of SIP Holdings authorizing the acquisition of the IP portfolio from SMT Inc. and the entry into each of the intercompany agreements contemplated by the Transaction, including the IP Assignment Agreement, the License-Back Agreement, the rest-of-world license agreements, the Cost-Plus R&D Services Agreement, and the Intercompany Loan Agreement.
8. Confirmation of the registered office of SIP Holdings at Unit 14, Corrib Technology Park, Headford Road, Galway, H91 XR72, Ireland, together with any filings made with the CRO in connection with the establishment of the registered office.
C. SMT Inc. Corporate Documents
9. Certificate of incorporation for Solstice Medical Technologies Inc. (Delaware File No. 7482916), together with any certificates of amendment, certificates of merger, or other amendments thereto.
10. A current certificate of good standing (or certificate of status) for SMT Inc. issued by the Delaware Secretary of State, dated no earlier than January 1, 2024.
11. Board resolutions of SMT Inc. authorizing the transfer of the IP portfolio to SIP Holdings and the entry into all related intercompany agreements, including the IP Assignment Agreement, the License-Back Agreement, and the Cost-Plus R&D Services Agreement.
D. SBD Corporate Documents
12. Board resolutions of Solstice Biomedical Devices Ltd. approving the IP migration Transaction, including the IP transfer from SMT Inc. to SIP Holdings, the equity contribution of €16.7M to SIP Holdings, the intercompany loan of €180.0M to SIP Holdings, and all related intercompany agreements.
13. Evidence that Pinnacle Growth Equity Partners Fund III, L.P. has approved the Transaction, including any written consent, investment committee approval, or advisory board approval required for material intercompany transactions exceeding €10M, as we understand is required pursuant to the shareholder agreement or applicable governance provisions. If such approval was obtained from the investment committee of Pinnacle Growth Equity Advisors III LLC (Managing Partner: Jonathan Whitfield), please provide a copy of the relevant minutes or written consent.
14. Any additional shareholder consents, investor side-letter waivers, or governance approvals required in connection with the Transaction.
II. IP VALUATION AND TRANSFER PRICING DOCUMENTATION
A. Whitmore Valuation Advisors LLC — Draft IP Valuation Report
15. A full and complete copy of the draft IP valuation report dated January 29, 2024, prepared by Whitmore Valuation Advisors LLC ("WVA") (project reference WVA-2023-1187; lead professional: Marcus Whitmore, ASA, Managing Director; address: 900 Third Avenue, 18th Floor, New York, NY 10022), including all appendices, schedules, exhibits, and supporting workpapers. We understand that the valuation date is December 31, 2023, and that the report concludes a fair market value for the IP portfolio of $214.5 million.
16. Detailed information regarding the valuation methodology employed, which we understand to be the income approach utilizing a discounted cash flow analysis, including:
(a) The derivation of the weighted-average cost of capital ("WACC") of 13.5%, including all inputs, assumptions, and comparable company data used in determining the discount rate;
(b) The determination of the remaining weighted-average useful life of the IP portfolio of 12.8 years, including any analyses of patent expiration dates, technology obsolescence, and product life-cycle considerations;
(c) All financial projections and revenue forecasts used as inputs to the discounted cash flow model;
(d) All supporting schedules, including comparable transaction analyses, comparable licensing agreement analyses, and any sensitivity analyses performed (e.g., variations in discount rate, revenue growth assumptions, and useful life); and
(e) Any management representation letters or certifications provided by SBD or SMT Inc. to WVA in connection with the valuation.
17. Any draft or final transfer-pricing benchmarking study prepared by WVA supporting the arm's-length nature of the royalty rate of 8.0% of net sales to be charged under the License-Back Agreement between SIP Holdings and SMT Inc.
18. WVA's intercompany debt pricing analysis supporting the arm's-length nature of the 3.75% per annum fixed interest rate on the €180.0M intercompany loan from SBD to SIP Holdings, including any comparable debt analyses, credit rating assessments for SIP Holdings, and spread analyses.
19. Rest-of-world royalty rate benchmarking analyses supporting the range of royalty rates of 4.0% to 6.5% of net sales by territory for the license agreements between SIP Holdings and SBD and/or other group entities outside North America.
B. Arm's-Length Royalty Rate Documentation
20. The complete benchmarking analysis or comparable uncontrolled transaction ("CUT") study used to determine that the 8.0% royalty rate for the exclusive license-back from SIP Holdings to SMT Inc. for the North American territory satisfies the arm's-length standard under Section 482 of the Code and the Treasury Regulations promulgated thereunder.
21. A functional analysis and characterization of each entity's contributions with respect to the development, enhancement, maintenance, protection, and exploitation ("DEMPE") of the intellectual property, including a detailed description of:
(a) The functions performed, assets used, and risks assumed by SMT Inc. in its capacity as the historical developer and current user of the IP;
(b) The functions performed, assets used, and risks assumed by SIP Holdings in its capacity as the post-transaction owner of the IP;
(c) The functions performed, assets used, and risks assumed by SBD and any other group entities; and
(d) The allocation of DEMPE functions among group entities both before and after the Transaction.
22. Documentation of the territory-specific royalty rates, ranging from 4.0% to 6.5% of net sales, for the rest-of-world license agreements between SIP Holdings and SBD and/or other group entities, including the basis for any differentiation in rates by territory and the value-added functions performed locally.
23. The projected Year 1 royalty stream under the US License-Back Agreement, which we understand to be approximately $15.136 million (based on projected SMT Inc. net sales of $189.2 million multiplied by the 8.0% royalty rate), together with any projections for subsequent years.
III. TRANSACTION AGREEMENTS (DRAFTS OR EXECUTED)
We request copies of all intercompany agreements, whether in draft or executed form, relating to the Transaction. To the extent that any agreement is still in the process of being negotiated or finalized, please provide the most recent draft together with any term sheets, letters of intent, or summaries of material outstanding issues.
A. IP Assignment Agreement
24. The draft or executed IP Assignment Agreement between Solstice Medical Technologies Inc. (as transferor) and Solstice IP Holdings DAC (as transferee), including all schedules and exhibits. We understand that the agreement provides for a purchase price of $214.5 million and that the IP being transferred includes:
(a) Forty-seven (47) granted US utility patents;
(b) Twelve (12) pending US patent applications;
(c) Associated trade secrets, technical know-how, engineering drawings, and manufacturing process documentation; and
(d) Proprietary software algorithms,
in each case relating to the "NaviPulse" catheter guidance platform and the "ClearVue" intra-operative cardiac imaging system.
25. Payment terms set forth in the IP Assignment Agreement, including the funding mechanism for the purchase price (which we understand to consist of a combination of the €180.0M intercompany loan from SBD to SIP Holdings and the €16.7M equity contribution from SBD to SIP Holdings).
B. License-Back Agreement
26. The draft or executed exclusive License-Back Agreement between SIP Holdings (as licensor) and SMT Inc. (as licensee), including all schedules and exhibits. We request particular attention to the following provisions:
(a) Territory: North America (United States and Canada, as we understand it);
(b) Royalty Rate: 8.0% of net sales;
(c) Definition of "Net Sales": The precise contractual definition, including any exclusions, deductions, or adjustments (e.g., returns, allowances, discounts, rebates, chargebacks, sales taxes, duties, and the like);
(d) Term and Termination: The initial term of the license, any renewal provisions, and the circumstances under which either party may terminate the agreement;
(e) Sublicensing: Any provisions permitting or restricting SMT Inc.'s ability to grant sublicenses to third parties or affiliates; and
(f) Payment Terms: The timing, currency, and mechanics of royalty payments.
C. Rest-of-World License Agreements
27. Drafts or executed copies of all license agreements between SIP Holdings and SBD and/or other group entities for the exploitation of the IP outside North America, together with all schedules and exhibits. We understand that the royalty rates under these agreements range from 4.0% to 6.5% of net sales, depending on the territory and the value-added functions performed by the local licensee. Please provide:
(a) A summary of each agreement, identifying the parties, territory, royalty rate, and material terms;
(b) The basis for any differentiation in royalty rates across territories; and
(c) Any provisions regarding sublicensing, exclusivity, and the scope of rights granted.
D. Cost-Plus R&D Services Agreement
28. The draft or executed Cost-Plus R&D Services Agreement between SMT Inc. (as service provider) and SIP Holdings (as service recipient), including all schedules and exhibits. We request particular attention to the following:
(a) Mark-up: Cost plus 8.0%;
(b) Scope of Services: A detailed description of the research and development services to be performed by SMT Inc. on behalf of SIP Holdings, including the specific R&D activities, milestones, deliverables, and any ongoing enhancement, maintenance, or improvement obligations;
(c) Personnel, Facilities, and Resources: Identification of the personnel, laboratory and testing facilities, equipment, and other resources allocated to contract R&D activities at SMT Inc.;
(d) IP Ownership Provisions: Confirmation that all intellectual property developed under the agreement vests in and is the sole property of SIP Holdings as the principal and owner of the IP; and
(e) Reporting and Billing: The frequency and format of cost reporting, invoicing, and payment.
E. Intercompany Loan Agreement
29. The draft or executed intercompany loan facility agreement between SBD (as lender) and SIP Holdings (as borrower), including all schedules, exhibits, and any ancillary security or subordination documentation. We understand the material terms to be as follows:
(a) Facility Amount: €180.0 million;
(b) Interest Rate: 3.75% per annum (fixed);
(c) Term: Ten (10) years, with a maturity date of March 1, 2034;
(d) Annual Interest: €6.75 million (calculated as €180.0M × 3.75%);
(e) Repayment Schedule: Interest-only payments during years 1 through 3 (March 1, 2024 through February 28, 2027); thereafter, equal annual principal installments of approximately €25.71 million (calculated as €180.0M ÷ 7) plus accrued interest, payable during years 4 through 10;
(f) Security and Covenants: Any security granted by SIP Holdings in favor of SBD (including any pledge of IP assets, assignment of receivables, or other collateral), and any financial or operational covenants; and
(g) Subordination or Priority: Any provisions addressing the subordination or priority of the intercompany loan relative to any other obligations of SIP Holdings.
F. Shareholder Capital Contribution Documentation
30. Documentation evidencing the €16.7 million shareholder capital contribution from SBD to SIP Holdings, which we understand represents the equity funding of the balance of the purchase price for the IP portfolio beyond the proceeds of the intercompany loan. This should include:
(a) The board resolution or written consent of SBD approving the capital contribution;
(b) The corresponding board resolution or written consent of SIP Holdings accepting the contribution;
(c) Evidence of the transfer of funds (or confirmation that the transfer is to occur simultaneously with closing); and
(d) Any share issuance or other documentation reflecting the contribution in SIP Holdings' books and records.
IV. US TAX AND FINANCIAL INFORMATION FOR SMT INC.
A. Tax Returns and Basis Information
31. Complete copies of the federal income tax returns (IRS Form 1120) filed by Solstice Medical Technologies Inc. for fiscal years 2021, 2022, and 2023, including all schedules, attachments, and any amended returns.
32. Complete copies of the state income tax returns filed by SMT Inc. for the Commonwealth of Massachusetts and any other states in which SMT Inc. files income or franchise tax returns, for fiscal years 2021, 2022, and 2023.
33. A detailed schedule of the adjusted tax basis of SMT Inc. in each item of intellectual property included in the IP portfolio, as currently reflected on SMT Inc.'s books and records for federal income tax purposes. We understand the aggregate adjusted tax basis to be approximately $11.3 million, reflecting that the IP portfolio has been substantially fully amortized or expensed for US tax purposes.
34. Complete depreciation and amortization schedules for all IP assets included in the transfer, including Section 197 intangible amortization schedules, Section 174 research and experimental expenditure deductions, and any other relevant schedules.
35. A calculation of the built-in gain for purposes of Section 367(d) of the Code, which we understand to be approximately $203.2 million (calculated as the fair market value of $214.5 million minus the adjusted tax basis of $11.3 million).
36. Documentation of any prior Section 482 adjustments, transfer-pricing audits, or IRS correspondence involving SMT Inc. or any other member of the SBD group.
37. Copies of any gain recognition agreements previously filed by SMT Inc. or any related party under Section 367 of the Code and the Treasury Regulations thereunder.
B. FY2023 Financial and Deduction Data
38. Confirmation of SMT Inc.'s FY2023 revenue of $189.2 million, which we understand represents approximately 50.1% of SBD's consolidated revenues (at the average exchange rate of €1.00 = $1.09 for FY2023).
39. A detailed schedule of SMT Inc.'s FY2023 total deductions of $174.8 million, which information is needed for purposes of calculating the base erosion percentage under Section 59A of the Code (the "BEAT"). This schedule should include a comprehensive breakdown of total deductions by category, including, without limitation:
(a) Cost of goods sold;
(b) Selling, general, and administrative expenses;
(c) Research and development expenses;
(d) Depreciation and amortization;
(e) Interest expense;
(f) Compensation and employee benefits; and
(g) All other deductions.
40. Identification and quantification of any existing base erosion payments (as defined in Section 59A(d) of the Code) included within the $174.8 million of total deductions, including any deductible payments made to foreign related parties (e.g., management fees, service charges, royalties, or interest payments to SBD or other non-US affiliates).
41. Confirmation of SMT Inc.'s employee headcount, which we understand to be approximately 580 employees as of December 31, 2023.
C. GILTI and Subpart F Data
42. Qualified business asset investment ("QBAI") calculations for SIP Holdings, including a detailed schedule of all tangible depreciable property (if any) held by SIP Holdings, determined on an adjusted basis under the alternative depreciation system within the meaning of Section 951A(d)(1) of the Code and the Treasury Regulations thereunder.
43. Information regarding any existing Subpart F income inclusions (under Section 951 of the Code) for SBD group entities that are controlled foreign corporations within the meaning of Section 957.
44. Documentation of any prior GILTI high-tax exclusion elections made by SMT Inc. or any US shareholder of SBD group controlled foreign corporations under Treasury Regulation § 1.951A-2(c)(7).
V. SBD GROUP CONSOLIDATED FINANCIAL INFORMATION
A. Audited Financial Statements
45. Complete copies of the audited consolidated financial statements of Solstice Biomedical Devices Ltd. for fiscal years 2021, 2022, and 2023, as prepared in accordance with International Financial Reporting Standards ("IFRS") and audited by Pemberton Hale LLP (lead audit partner: Aisling Brennan), including the independent auditor's report, balance sheet, income statement, statement of comprehensive income, statement of changes in equity, statement of cash flows, and all notes to the financial statements.
46. We understand that FY2023 consolidated revenue was €347.6 million and that FY2023 consolidated EBITDA was approximately €78.4 million, representing an EBITDA margin of approximately 22.5%. Please confirm these figures and provide any reconciliation of EBITDA to operating income or net income.
47. Revenue and profitability breakdown by entity, geographic segment, and product line, with specific identification of revenues and operating margins attributable to the NaviPulse catheter guidance platform and the ClearVue intra-operative cardiac imaging system, respectively.
B. Segment and Entity-Level Financials
48. Standalone (unconsolidated) financial statements for SMT Inc. for FY2023, including the income statement, balance sheet, and statement of cash flows, prepared in accordance with US GAAP or on such other basis as maintained by SMT Inc. for statutory or management reporting purposes.
49. Standalone financial statements or, if not yet available, pro forma financial projections for SIP Holdings for the period commencing on the Transaction effective date through the end of FY2024 and for at least FY2025 and FY2026.
50. Financial projections for SIP Holdings for at least five years following the Transaction, including:
(a) Projected royalty income from all licensees (SMT Inc. and rest-of-world licensees);
(b) Projected capital allowance deductions under Section 291A of the Taxes Consolidation Act 1997 ("TCA 1997") of approximately €13.12 million per year, based on an IP cost of approximately €196.8 million (being $214.5 million converted at €1.00 = $1.09) amortized over the 15-year statutory amortization period;
(c) Projected interest expense on the €180.0 million intercompany loan;
(d) Projected cost-plus R&D service charges payable to SMT Inc.; and
(e) Projected Irish taxable trading income after the foregoing deductions.
C. Worldwide Employee Information
51. Confirmation of the SBD group's worldwide employee headcount, which we understand to be approximately 1,640 employees.
52. A breakdown of employees by entity and jurisdiction, identifying the number of employees at SBD (Ireland), SMT Inc. (United States), SIP Holdings (Ireland), and any other group entity.
VI. INTELLECTUAL PROPERTY PORTFOLIO DETAILS
A. Patent Schedule
53. A complete and detailed schedule of all forty-seven (47) granted US utility patents included in the IP portfolio to be transferred, including for each patent:
(a) US patent number;
(b) Title of the invention;
(c) Filing date (and any priority dates);
(d) Issue date;
(e) Expiration date (including the effect of any patent term adjustments or extensions);
(f) Named inventor(s);
(g) Current assignee (which we understand to be SMT Inc. in all cases);
(h) Classification by product line (i.e., whether the patent relates primarily to the NaviPulse catheter guidance platform, the ClearVue intra-operative cardiac imaging system, or both); and
(i) Current status (active, maintained, etc.) and any ongoing maintenance fee obligations.
54. A complete and detailed schedule of all twelve (12) pending US patent applications included in the IP portfolio, including for each application:
(a) US patent application number;
(b) Title of the invention;
(c) Filing date;
(d) Current prosecution status (e.g., pending examination, office action outstanding, appeal, allowance);
(e) Named inventor(s); and
(f) Classification by product line.
55. A schedule of any foreign patent filings, Patent Cooperation Treaty ("PCT") international applications, European Patent Office ("EPO") applications, or other international patent rights associated with the US patents and patent applications in the portfolio, together with their current status.
B. Trade Secrets and Know-How
56. An inventory or descriptive summary of all trade secrets, technical know-how, engineering drawings, manufacturing process documentation, proprietary software algorithms, and other non-patent intellectual property assets included in the transfer. This inventory need not disclose the substance of any trade secret but should identify each category of intangible asset, its general subject matter, and its relationship to the NaviPulse and/or ClearVue product lines.
57. A description of the confidentiality and trade secret protection measures currently in place at SMT Inc., including:
(a) Employee confidentiality and invention assignment agreements;
(b) Physical and electronic access controls;
(c) Non-disclosure agreements with third-party contractors, suppliers, and collaborators; and
(d) Any trade secret audits or assessments conducted within the past three years.
C. IP Ownership and Encumbrances
58. Chain of title documentation for all forty-seven (47) granted patents and twelve (12) pending patent applications, including all assignments, licenses, and other transfers recorded with the US Patent and Trademark Office.
59. A certification or representation, from SBD's internal counsel or from Dalton Byrne & Partners, confirming that no liens, security interests, pledges, encumbrances, or other third-party rights exist with respect to any item of intellectual property included in the IP portfolio, or, to the extent any such encumbrances exist, a complete description thereof.
60. Copies of any existing license agreements, collaboration agreements, joint development agreements, or other third-party agreements affecting the IP portfolio or any portion thereof, including any agreements that may require consent to assignment or that contain change-of-control provisions.
VII. IRISH TAX AND REGULATORY INFORMATION
A. Section 291A TCA 1997 — Specified Intangible Asset Qualification
61. An analysis, memorandum, or written confirmation from Harrington & Cahill (Niamh O'Sullivan, Tax Partner) that the IP portfolio to be acquired by SIP Holdings qualifies as a "specified intangible asset" within the meaning of Section 291A of the Taxes Consolidation Act 1997, as amended, and is therefore eligible for capital allowances (tax amortization) over the statutory period.
62. Confirmation or detailed calculation of the cost of the IP portfolio in euro for purposes of Section 291A, which we understand to be approximately €196.8 million (calculated as $214.5 million converted at the exchange rate of $1.09 per €1.00).
63. Confirmation of the applicable statutory amortization period of 15 years and the resulting annual capital allowance of approximately €13.12 million (calculated as €196.8 million divided by 15 years).
64. Copies of any guidance, correspondence, opinions, or advance opinions received from or exchanged with the Irish Revenue Commissioners regarding the availability or quantum of capital allowances under Section 291A in connection with this Transaction.
B. Irish Transfer Pricing Documentation
65. All transfer pricing documentation that has been prepared, or is in the process of being prepared, in respect of the Transaction and the intercompany arrangements among SBD group entities, including documentation prepared pursuant to the transfer pricing rules as amended by the Finance Act 2019 (which introduced OECD-aligned transfer pricing standards in Ireland, effective for accounting periods commencing on or after January 1, 2020).
66. The OECD-compliant master file and local file for the SBD group, if available, or a description of the status of preparation of these documents.
67. Confirmation of arm's-length compliance for all intercompany transactions forming part of the Transaction, including:
(a) The IP purchase price of $214.5 million;
(b) The royalty rates (8.0% for North America; 4.0%–6.5% for rest-of-world);
(c) The intercompany loan interest rate of 3.75% per annum; and
(d) The cost-plus R&D services mark-up of 8.0%.
C. SIP Holdings Substance
68. A detailed description of the management and control of SIP Holdings exercised in Ireland, including:
(a) The names, qualifications, tax residence, and locations of the directors of SIP Holdings;
(b) The location and frequency of board meetings, together with copies of any board meeting agendas, minutes, or written resolutions adopted to date;
(c) A description of the Irish-based personnel (employees, contractors, or secondees) who will be responsible for the day-to-day management and administration of SIP Holdings, including their roles, responsibilities, and reporting lines;
(d) A description of the decision-making processes and operational activities conducted by SIP Holdings in Ireland, including IP portfolio management, licensing strategy, royalty administration, and R&D oversight; and
(e) Any employment agreements, secondment agreements, or contractor arrangements entered into by SIP Holdings in connection with establishing its Irish operational presence.
D. US-Ireland Income Tax Treaty — Limitation on Benefits
69. Information relevant to the determination of whether SIP Holdings qualifies for benefits under the US-Ireland Income Tax Treaty, with particular attention to Article 12 (Royalties) and the Limitation on Benefits ("LOB") article, including: